Genocea Beats Investor Claims It Hid Truth About Herpes Drug

Law360 (December 6, 2018, 7:55 PM EST) -- A Massachusetts federal judge dismissed a proposed investor class action Thursday against Genocea Biosciences Inc., saying accusations that the company hid negative test results before announcing it could not finance ongoing trials for a genital herpes immunotherapy were not sufficiently supported for the case to proceed.

The case largely rested on the investors' claim that the Cambridge-based company deliberately withheld the results of six-month followup tests for the drug's second phase of clinical trials in early 2017. But U.S. District Judge Patti B. Saris said in her order that, because the company later released 12-month testing results that did not cause...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Subscribers Only

Nature of Suit

Subscribers Only

Judge

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Government Agencies

Judge Analytics

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!